UNC Collaborative for Maternal & Infant Health

UNC Collaborative for Maternal & Infant Health

Improving the health of North Carolina's women and infants

Menu
  • Home
  • About Us
    • Overview
    • Our Team
    • Collaborations & Partnerships
    • Internships
    • Newsletters
    • Legacy
    • Donate
    • Subscribe
    • Contact Us
    • Close
  • Key Services
    • Family-Centered Care
      • Care Coordination
      • Referrals to UNC
      • Special Infant Care Clinic
      • Prenatal Diagnosis and Fetal Therapy
      • Perinatal Loss
      • Clinic Partners
    • Technical Assistance
      • Preconception Health
      • Tobacco Resources
      • Data Services
    • Close
  • Patient Education Materials
  • Resources for Practice
    • OB Algorithms
    • UNC Internal Protocols
    • 17P (Progesterone)
    • UNC Lactation Program
    • CCNC PMH Care Pathways
    • NICU Clinical Guidelines
    • Trisomy 13 and Trisomy 18
    • Close
  • State and National Programs
    • North Carolina Perinatal Region IV Provider Support Network
    • Child Fatality Task Force / NC Perinatal Plan
    • NC 17P Project
    • You Quit, Two Quit
    • Safe Infant Sleep
    • Perinatal/Neonatal Outreach Coordination (PNOC) project
    • National Preconception Health & Health Care Initiative (PCHHC)
    • Collaborative Improvement and Innovation Network on Infant Mortality (IM CoIIN)
    • The North Carolina Perinatal Health and Incarceration Working Group
    • Every Woman Southeast
    • Close
  • Research
    • 4th Trimester Project
    • Bowes Cefalo Research Award
    • Care4Moms
    • Close
  • Search

Statement on FDA Advisory Committee Decision

In Oct 2019, a Food and Drug Administration advisory committee recommended that approval be withdrawn for Makena – 17-α-hydroxyprogesterone caproate or “17P.”  In Oct 2020, the FDA’s Center for Drug Evaluation and Research issued the recommendation that Makena and its generic equivalents be pulled from the market. There has not yet been a final decision, and Makena and generic 17P remain on the market.  Both the American College of Obstetrics and Gynecology and the Society for Maternal-Fetal Medicine have issued statements recommending no changes to the existing clinical guidance regarding 17P.  As recommended earlier, providers should engage in a framework of shared decision-making with at-risk patients to decide whether or not to use 17P.  Please see this handout for more information.

Questions? Email Erin McClain.

Subscribe to Updates

Contact Us

Room 216 MacNider
Campus Box 7181
Chapel Hill, NC 27599-7181

The University of North Carolina at Chapel Hill

Find Us

Info on visiting UNC Hospitals

Support Us

Donate Now

Connect With Us

  • Email
  • LinkedIn
  • Twitter

Copyright © 2021 UNC Center for Maternal & Infant Health · All Rights Reserved · Website by Tomatillo Design